Menu

Investors

2026 First quarter announcement

We announced our first quarter 2026 results on Wednesday 29 April. ​

Quarterly resultsAnnual Report 2025
Luke Miels CEO
Close video

We’re confident in our future

With our strong momentum and improving outlook for sustained growth through the decade, we're confident in our ability to deliver human health impact at scale, worldwide.

Why invest in GSK?

Speeches and presentations

Julie Brown

BNP Paribas Exane CEO Conference

03 June 2026

Julie Brown, Chief Financial Officer, attended the BNP Paribas Exane CEO Conference in Paris on Wednesday, 3 June 2026.

Hesham Abdullah portrait

Jefferies Global Healthcare Conference

03 June 2026

Hesham Abdullah, SVP, Global Oncology R&D, participated in the Jefferies Global Healthcare Conference in New York on Wednesday, 3 June 2026.

GSK Hepatitis B science image

Review of bepirovirsen Phase III data presented at the European Association for the Study of the Liver (EASL)

28 May 2026

Following EASL on 28th May, we hosted a call with Nina Mojas, President, Global Product Strategy, Kaivan Khavandi, SVP, R&D Head Respiratory, Immunology & Inflammation, Melanie Paff, VP, MDL HBV Program and Prof Seng Gee Lim, Director of Hepatology, National University Health System, Singapore, highlighting our data from the B-Well 1 and B-Well 2 phase III pivotal studies.

David Redfern

Barclays European Leadership Conference

21 May 2026

David Redfern, President Corporate Development, attended the Barclays European Leadership Conference in London on Thursday, 21 May 2026.

David Redfern

Rothschild & Co Global Equities Conference

12 May 2026

David Redfern, President Corporate Development, attended the Rothschild & Co's upcoming Global Equities Conference in Toronto on Tuesday, 12 May 2026.

Shareholder information

Shareholder information

GSK dividend

GSK laboratory photo

Dividend calculators (GBp/USD)

Calculate an estimate of your dividend payment

GSK lab equipment photo

Dividend calendar

Details of our dividend timetable by quarter

GSK share price

Share price tool

Detailed information on GSK's share price, including an interactive chart

Go to share price tool

Behind the Science

Read our latest articles

‘It’s always there’: Learning to live with chronic hepatitis B

‘The roar I hear is the next stage of the rocket firing’: MAPS technology and the new age of vaccine development

Antibody-drug conjugates: Advancing the search for more targeted cancer treatment

Mapping disease at the cellular level: A single-cell revolution in drug discovery

Why adults aged 50 years and older with certain long-term health conditions need to make their move to help protect against this common respiratory virus

'The ever-present threat of contracting a UTI means my daily routine is ruled by measures to reduce my risk'

'We’re innovating to help keep COPD patients out of hospital and exacerbation-free'

'Prevention is the best medicine to stop disease before it starts'

‘I was the sickest anyone could ever be’: Why young people are at risk of meningitis and what needs to change to reduce it

‘Digital biological twins and organoids might sound like sci-fi, but they’re real – and we’re using them to fight cancer’

Behind the Science magazine
two scientists talking

Get in touch with our investor team

Investor contact details

You might also like

Pipeline

Our pipeline is focused on unlocking the science of the immune system and advanced technologies to develop innovative medicines and vaccines

Our leading scientists

Meet the world-leading scientists who are working to bring innovative medicines and vaccines to patients

Governance

At GSK we are committed to operating at the highest standards of corporate governance

Continue to Media